ArticleInternational journal of clinical oncology2024

Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan.

Takuto Hara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.